Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Johann S. de Bono(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research), Pasquale Rescigno(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Raquel Pérez-López(Vall d'Hebron Institut de Recerca), Bora Gürel(Institute of Cancer Research), Ursula McGovern(University College Hospital), David Dolling(Institute of Cancer Research), Matthew Clarke(Institute of Cancer Research), Rob Chandler(Royal Marsden NHS Foundation Trust), Ben Fulton(Beatson West of Scotland Cancer Centre), Robert J. Jones(Beatson West of Scotland Cancer Centre), Antonella Petermolo(Royal Marsden NHS Foundation Trust), Carlo Messina(Royal Marsden NHS Foundation Trust), Nina Tunariu(Leicester Royal Infirmary), Emma Hall(Institute of Cancer Research), Susana Miranda(Royal Marsden NHS Foundation Trust), Shahneen Sandhu(The University of Melbourne), Omi Parikh(Royal Blackburn Teaching Hospital), Mark Atkin(Institute of Cancer Research), Christy Ralph(University of Leeds), Núria Porta, Tony Elliott(The Christie Hospital), Daniel Nava Rodrigues(Institute of Cancer Research), Zafeiris Zafeiriou(Royal Marsden NHS Foundation Trust), Suzanne Carreira(Institute of Cancer Research), Maialen Barrero(Royal Marsden NHS Foundation Trust), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Mariane Fontes(Royal Marsden NHS Foundation Trust), Mohini Varughese(Musgrove Park Hospital), Cláudia Bertan(Institute of Cancer Research), Suneil Jain(Queen's University Belfast), Semini Sumanasuriya(Institute of Cancer Research)
Cited by 303
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k